Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics entities : Aclaris therapeutics, inc. save search
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.2%
H: 2.39%
C: 1.34%
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 2.48%
H: 10.48%
C: -3.23%
year update therapeutics financial results
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 14.72%
H: 17.92%
C: 9.43%
business review therapeutics
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Published: 2024-01-10 (Crawled : 12:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -16.41%
H: 6.54%
C: -6.07%
ati-1777 dermatitis trial therapeutics results
Aclaris Therapeutics Provides Corporate Update
Published: 2023-12-19 (Crawled : 21:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -2.78%
H: 0.84%
C: -5.71%
update therapeutics
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
Published: 2023-12-05 (Crawled : 21:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 9.49%
H: 6.48%
C: -5.56%
pharma patent license therapeutics agreement
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -85.28%
H: 0.0%
C: -7.87%
ati-450 update trial therapeutics results
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 1.12%
H: 5.06%
C: 0.92%
update therapeutics financial results
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
Published: 2023-10-03 (Crawled : 11:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 0.97%
H: 2.65%
C: -7.94%
ati-1777 dermatitis therapeutics study
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Published: 2023-09-20 (Crawled : 11:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -0.27%
H: 0.88%
C: -8.51%
conference global therapeutics
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
Published: 2023-09-18 (Crawled : 11:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -5.75%
H: 0.0%
C: -1.46%
ati-2138 positive trial therapeutics results
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-08-07 (Crawled : 11:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: -8.14%
update therapeutics financial results
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
Published: 2023-06-13 (Crawled : 11:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 1.3%
H: 8.34%
C: 1.18%
ati-450 therapeutics study
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
Published: 2023-06-02 (Crawled : 11:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 1.15%
H: 3.64%
C: -0.11%
therapeutics
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-05-08 (Crawled : 11:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -3.79%
H: 1.04%
C: -2.78%
update therapeutics financial results
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
Published: 2023-05-02 (Crawled : 11:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -0.54%
H: 0.98%
C: -2.72%
therapeutics financial results
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Published: 2023-03-27 (Crawled : 12:20) - biospace.com/
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 0.37%
H: 3.02%
C: 1.24%
conference disease therapeutics
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -40.53%
H: 1.84%
C: -6.97%
ati-450 topline therapeutics study
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
Published: 2023-02-23 (Crawled : 14:00) - biospace.com/
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 0.39%
H: 2.75%
C: 0.24%
year therapeutics financial update results
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
Published: 2023-02-09 (Crawled : 22:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -0.51%
H: 3.84%
C: 3.63%
biopharma global conference therapeutics
Aclaris Therapeutics Provides 2023 Outlook
Published: 2023-01-06 (Crawled : 12:20) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 0.72%
H: 8.44%
C: 7.89%
therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.